Your browser doesn't support javascript.
loading
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Keegan, Niamh M; Furney, Simon J; Walshe, Janice M; Gullo, Giuseppe; Kennedy, M John; Smith, Diarmuid; McCaffrey, John; Kelly, Catherine M; Egan, Keith; Kerr, Jennifer; Given, Mark; O'Donovan, Peter; Hernando, Andres; Teiserskiene, Ausra; Parker, Imelda; Kay, Elaine; Farrelly, Angela; Carr, Aoife; Calzaferri, Giulio; McDermott, Ray; Keane, Maccon M; Grogan, Liam; Breathnach, Oscar; Morris, Patrick G; Toomey, Sinead; Hennessy, Bryan T.
Afiliación
  • Keegan NM; Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Furney SJ; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
  • Walshe JM; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland.
  • Gullo G; Genomic Oncology Research Group, Department of Physiology & Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Kennedy MJ; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
  • Smith D; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • McCaffrey J; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
  • Kelly CM; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • Egan K; Department of Medical Oncology, St James's Hospital, Dublin, Ireland.
  • Kerr J; Department of Endocrinology, Beaumont Hospital, Dublin, Ireland.
  • Given M; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • O'Donovan P; Department of Medical Oncology, Mater Misericordia University Hospital, Dublin, Ireland.
  • Hernando A; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • Teiserskiene A; Department of Medical Oncology, Mater Misericordia University Hospital, Dublin, Ireland.
  • Parker I; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland.
  • Kay E; Department of Radiology, Beaumont Hospital, Dublin, Ireland.
  • Farrelly A; Department of Radiology, Beaumont Hospital, Dublin, Ireland.
  • Carr A; Genomic Oncology Research Group, Department of Physiology & Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Calzaferri G; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • McDermott R; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • Keane MM; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • Grogan L; Department of Pathology, Beaumont Hospital, Dublin, Ireland.
  • Breathnach O; Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Morris PG; Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Toomey S; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
  • Hennessy BT; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
Cancers (Basel) ; 13(6)2021 Mar 11.
Article en En | MEDLINE | ID: mdl-33799597
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Irlanda
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Irlanda